Search

GlaxoSmithKline PLC

Avatud

SektorTervishoid

1,388.5 0.04

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1368.5

Max

1397

Põhinäitajad

By Trading Economics

Sissetulek

559M

501M

Müük

105M

8.1B

P/E

Sektori keskmine

21.557

57.333

Aktsiakasum

23.2

Dividenditootlus

4.79

Kasumimarginaal

6.172

Töötajad

68,629

EBITDA

-52M

1.1B

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+13.6% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

4.79%

2.63%

Järgmine tulemuste avaldamine

30. apr 2025

Järgmine dividendimakse kuupäev

10. juuli 2025

Järgmine aktsia dividendi kuupäev (ex-date)

15. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-5.9B

54B

Eelmine avamishind

1388.46

Eelmine sulgemishind

1388.5

GlaxoSmithKline PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. apr 2025, 09:39 UTC

Suurimad hinnamuutused turgudel

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

5. veebr 2025, 11:32 UTC

Tulu

GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook -- 2nd Update

5. veebr 2025, 08:56 UTC

Tulu

Correction to GSK Article

5. veebr 2025, 08:24 UTC

Tulu

GSK Issues $2.5 Billion Buyback, Raises Midterm Outlook After Beating Market Views -- Update

5. veebr 2025, 07:43 UTC

Tulu

GSK Expects Further Profit Growth After Beating Market Views

23. apr 2025, 21:48 UTC

Peamised uudised

Shingles Vaccine Appears to Lower Dementia Risk -- WSJ

23. apr 2025, 20:47 UTC

Peamised uudised

Shingles Vaccine Appears to Lower Dementia Risk -- WSJ

23. apr 2025, 20:40 UTC

Peamised uudised

Shingles Vaccine Appears to Lower Dementia Risk -- WSJ

15. apr 2025, 09:55 UTC

Market Talk

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

9. apr 2025, 07:23 UTC

Market Talk

Pharma Stocks Tumble After Trump Floats Tariffs on Industry -- Market Talk

3. apr 2025, 08:41 UTC

Market Talk

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

3. apr 2025, 08:36 UTC

Market Talk

U.K. Pharma to Have Some Share-Price Volatility But Long-Term Outlook Remains Intact -- Market Talk

3. apr 2025, 07:51 UTC

Market Talk

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

2. apr 2025, 09:27 UTC

Kuumad aktsiad

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

26. märts 2025, 22:29 UTC

Peamised uudised

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- 2nd Update

26. märts 2025, 19:19 UTC

Peamised uudised

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- Update

26. märts 2025, 17:39 UTC

Peamised uudised

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- WSJ

19. märts 2025, 14:50 UTC

Peamised uudised

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

17. märts 2025, 09:00 UTC

Peamised uudised

Pfizer Has a New Playbook for Reviving Sales -- And It's Starting to Pay Off -- WSJ

24. veebr 2025, 07:05 UTC

Omandamised, ülevõtmised, äriostud

GSK Completes Acquisition of IDRx

14. veebr 2025, 11:38 UTC

Peamised uudised
Tulu

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

14. veebr 2025, 11:30 UTC

Peamised uudised
Tulu

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

5. veebr 2025, 15:33 UTC

Market Talk
Tulu

GSK's Pipeline Has to Prove It Can Counter Concerns Over Vaccine Business -- Market Talk

5. veebr 2025, 08:38 UTC

Market Talk
Tulu

GSK Needs to Show It Can Navigate Vaccines Challenge -- Market Talk

5. veebr 2025, 07:05 UTC

Tulu

GSK PLC Had Seen 2031 Sales Outlook at More Than GBP38B

5. veebr 2025, 07:04 UTC

Tulu

GSK PLC Sees 2031 Sales Outlook at More Than GBP40B

5. veebr 2025, 07:03 UTC

Tulu

GSK PLC Sees 2025 Adjusted EPS Growth of 6%-8%

5. veebr 2025, 07:03 UTC

Tulu

GSK PLC Raises Mid-Term View

5. veebr 2025, 07:03 UTC

Tulu

GSK PLC Sees 2025 Adjusted Operating Growth of 6% - 8%

5. veebr 2025, 07:02 UTC

Tulu

GSK PLC Sees 2025 Turnover Growth of 3% to 5%

GlaxoSmithKline PLC Prognoos

Hinnasiht

By TipRanks

13.6% tõus

12 kuu keskmine prognoos

Keskmine 1,583.64 GBX  13.6%

Kõrge 2,290 GBX

Madal 1,350 GBX

Põhineb 11 Wall Streeti analüütiku instrumendi GlaxoSmithKline PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

11 ratings

1

Osta

8

Hoia

2

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.